CATCo Regulatory News (CAT)

24 May 2006 11:46

GoldmanSachs International24 May 2006 FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION Name of exempt principal trader Goldman Sachs International Company dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC Class of relevant security to which the Ordinary Sharesdealings being disclosed relate (Note 1) Date of dealing 23 May 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3) 5669500 13.20 GBP 12.9931 GBP Total number of securities sold Highest price received (Note 3) Lowest price received (Note 3) 5869075 13.20 GBP 12.9996 GBP (b) Derivatives transactions (other than options) Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3)e.g. CFD CFD Long 200000 13.05 GBPCFD Long 4227 13.05 GBPCFD Short 78000 13.20 GBP (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of securities to Exercise Type, e.g. Expiry Option money purchasing, which the option relates American,e.g. call varying etc. (Note 5) price European date paid/received peroption etc. unit (Note 3) (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relatingto the voting rights of any relevant securities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form isreferenced. If none, this should be stated. Date of disclosure 24 May 2006 Contact name Peter Highton Telephone number +44-207-774-1935 Name of offeree/offeror with which connected AstraZenecaNature of connection (Note 6) Advisor Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange